# Erenumab-aooe for the Management of Trigeminal Neuropathic Pain.

> **NCT05142228** · PHASE2 · TERMINATED · sponsor: **University of Maryland, Baltimore** · enrollment: 5 (actual)

## Conditions studied

- Trigeminal Neuropathy

## Interventions

- **DRUG:** Erenumab-Aooe
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05142228
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-05-31
- **Primary completion:** 2022-10-27
- **Final completion:** 2022-10-27
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Low enrollment rate
- **Last updated:** 2024-03-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05142228

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05142228, "Erenumab-aooe for the Management of Trigeminal Neuropathic Pain.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05142228. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*